Tirzepatide Weight Loss Results: Month-by-Month Timeline
What to actually expect at week 1, week 4, month 3, month 6, and month 12 on tirzepatide. Real trial data, average loss per week, and what to do if you're not losing.
01 The SURMOUNT-1 timeline
SURMOUNT-1 is the largest published phase 3 trial of tirzepatide for weight management — 2,539 adults with obesity, randomized to placebo or tirzepatide 5/10/15 mg, followed for 72 weeks. Below is the average % weight loss for the 15 mg arm at major timepoints. This is the published "average patient" — yours may be faster or slower.
SURMOUNT-1, tirzepatide 15 mg arm. Source: Jastreboff et al., NEJM 2022.
02 1-month tirzepatide results
Average: 2.5–3% of starting body weight (5–7 lb in a 200-lb adult).
Month 1 is the 2.5 mg starter dose period. This dose is sub-therapeutic by design — its job is to let your gut adapt to the GLP-1/GIP signal before increasing to the first true weight-loss dose (5 mg). Most weight lost in month 1 is some real fat plus some water and glycogen as your eating pattern shifts.
Subjective experience in month 1 is more important than the scale: most patients notice a dramatic decrease in food cravings, reduced "food noise," and earlier satiety with smaller portions. These changes reliably predict whether you'll respond to higher doses.
03 3-month results
Average: 7–8% of starting body weight (14–16 lb in a 200-lb adult).
By month 3, most patients have titrated through 2.5 mg → 5 mg → 7.5 mg. The 5 mg and 7.5 mg doses are the first truly therapeutic dosing levels, and weight loss accelerates noticeably. This is the phase where clothes start fitting differently. Many patients describe the 8–12 week mark as the moment they "knew it was working."
Side effects, if present, usually peak in this window with each dose escalation, then resolve.
04 6-month results
Average: 13–15% of starting body weight (26–30 lb in a 200-lb adult).
Six months is a critical inflection point. By now, most patients have reached a maintenance dose (5, 7.5, 10, 12.5, or 15 mg) and are losing at a steadier weekly pace. The visible body changes — face, neck, waist — are obvious to others. This is the phase when about 60% of patients in SURMOUNT-1 had already lost more than 10% of starting body weight.
Hair shedding (telogen effluvium) often peaks here — 3–4 months after the steepest weight-loss phase. It's temporary; protein and iron support help. See hair loss for details.
05 12-month results & the plateau
Average: 18–20% of starting body weight (36–40 lb in a 200-lb adult).
At 12 months, most patients are well into a maintenance dose and the rate of loss has slowed. The fastest weight-loss phase (months 3–6) is over; the body has adapted to lower energy intake and is gradually adjusting set point. This is normal — and the plateau that follows isn't failure, it's biology.
SURMOUNT-1 followed patients out to 72 weeks (about 17 months) and saw continued loss, with the curve flattening but not stopping. The mean 15 mg arm loss at week 72 was 20.9%.
06 Average tirzepatide weight loss per week
| Phase | Average loss/week | Notes |
|---|---|---|
| Weeks 1–4 (2.5 mg) | 0.25–0.5 lb | Sub-therapeutic starter dose |
| Weeks 5–12 (5–7.5 mg) | 0.75–1.25 lb | Acceleration phase |
| Weeks 13–24 (7.5–10 mg) | 1.0–1.5 lb | Steepest weight loss |
| Weeks 25–52 (10–15 mg) | 0.5–1.0 lb | Steady losing phase |
| Weeks 52+ | 0.25–0.75 lb | Tapering as plateau approaches |
| Plateau / maintenance | ~0 lb | New set point reached |
These are averages. Real-world variation is wide: about 30% of trial participants lost >25% of body weight by week 72, and about 15% lost <5%. Genetic and metabolic differences explain most of the spread.
07 Not losing weight on tirzepatide? Troubleshoot
If you've been on at least 5 mg tirzepatide for 8+ weeks and the scale hasn't moved meaningfully, work through this checklist before assuming the drug isn't working.
Most common causes
- Still on the starter dose. 2.5 mg is sub-therapeutic. If you've been at 2.5 mg for 4+ weeks and haven't moved up, talk to your prescriber about advancing to 5 mg.
- Calorie creep. Tirzepatide reduces hunger but doesn't enforce a deficit. Common calorie blind spots: liquid calories (lattes, smoothies, alcohol), nuts and nut butters, "healthy" oils, condiments, mindless snacks. Track honestly for 7 days and you'll usually find the issue.
- Constipation masking real fat loss. A few pounds of constipated stool plus 5 lb of water retention can hide a real 5-lb fat loss for 2–3 weeks. Hydrate, fiber, magnesium.
- Cycle/PMS water retention if you're female pre-menopause. Compare weight at the same point in your cycle month-over-month, not week-to-week.
- Low protein. Counterintuitively, low protein leads to slower fat loss because of lost lean mass and lower satiety. Aim for 0.6–0.8 g/lb of goal body weight.
Less common but worth checking
- Untreated or under-treated hypothyroidism (TSH should be <2.5 for active weight loss)
- Untreated sleep apnea (causes insulin resistance and weight regain)
- Certain medications: prednisone, gabapentin, mirtazapine, beta blockers, some antipsychotics
- Cushing's syndrome (rare but worth ruling out if classic features present)
- PCOS (insulin resistance can blunt response)
08 Maintenance after reaching goal
Tirzepatide is treatment for chronic obesity, not a 6-month fix. SURMOUNT-4 specifically tested what happens when patients stop the drug after losing weight on it. The result: the average patient regained about 14% of body weight over 52 weeks — not all the way back to baseline, but most of the way.
Three reasonable maintenance strategies:
1. Stay at loss dose
Continue at the dose that got you to goal (e.g., 10 mg). Simplest. Maintains appetite suppression. Most expensive long-term.
2. Step down gradually
Reduce by 25–50% every 1–3 months and watch for regain. Many patients find a stable maintenance at 50% of their loss dose.
3. Microdose maintenance
Step down to sub-therapeutic doses (1–2 mg/week). Works for sensitive responders. See microdosing guide.
Regardless of strategy, the underlying principle is: weight regulation is biological, not motivational. Tirzepatide is one of the few effective long-term tools we have for the biology of obesity. Stopping it when goals are met often leads to regain — that's not failure on your part, it's the same hormonal pressure that caused the original weight gain.
Get tirzepatide for the long run.
Telehealth subscriptions make ongoing tirzepatide access straightforward — same monthly delivery, same provider relationship, same predictable cost. No re-applications, no prior auth gaps.
Find a Provider→09 Tirzepatide results FAQ
Most patients notice reduced appetite within 1–2 weeks. Visible weight loss usually begins in week 2–4. The full clinical effect builds over 4–6 months as you titrate to a maintenance dose. By month 6, the average SURMOUNT-1 participant on 15 mg had lost about 13–15% of body weight; by month 18, about 21%.
Appetite suppression typically begins within 3–7 days of the first injection and intensifies over the first 2–3 weeks. Most patients describe a noticeable drop in "food noise" — the constant background thinking about food — by the end of the first week. Some sensitive responders feel it within 24–48 hours.
On average, about 2.5–3% of starting body weight in the first month — roughly 5–7 lb in a 200-lb adult. The first month is the 2.5 mg starter dose, which is sub-therapeutic, so loss is modest. Loss accelerates as you titrate to 5 mg, 7.5 mg, and 10 mg over months 2–4.
In SURMOUNT-1, the average tirzepatide patient had lost about 7–8% of starting weight at 3 months — roughly 14–16 lb in a 200-lb adult. By this point most patients are at 5 mg or 7.5 mg dose. Real-world results vary widely depending on starting BMI, adherence, diet, and exercise.
About 13–15% of starting body weight at month 6 in SURMOUNT-1 (15 mg arm) — roughly 26–30 lb in a 200-lb adult. This is when most patients start seeing dramatic clothing-size changes. The slope of weight loss is steepest in months 3–6.
Roughly 0.5–1 lb per week on average across 18 months in trial data — sometimes faster in the first 6 months, slower in the second half. The first 4 weeks (starter dose) are typically slower (0.25–0.5 lb/wk), and weeks 12–24 are typically the fastest phase (1–1.5 lb/wk).
The most common reasons: (1) Still on starter dose — 2.5 mg is sub-therapeutic; (2) Not enough time — first 4–6 weeks show modest loss; (3) Calories crept up — appetite suppression doesn't guarantee a deficit if you're drinking calories or eating high-density snacks; (4) Constipation/water retention masking actual fat loss; (5) Underlying issues — untreated hypothyroidism, sleep apnea, certain medications. If you've been on at least 5 mg for 8+ weeks with strict tracking and no loss, it's worth a workup.
Tirzepatide doesn't typically "stop working" at a fixed timepoint, but most patients reach a plateau between months 12–18 as their body adapts to the new lower weight (a normal physiological adjustment). The plateau is the new set point, not failure. Going to a higher dose can sometimes restart loss; sometimes it can't, in which case the goal shifts from continued loss to maintenance.
There is no single answer. Some patients stay on their loss-phase dose (5–15 mg) indefinitely. Others step down 25–50% after reaching goal (e.g., 10 mg → 5 mg → 2.5 mg) and watch for regain. Still others microdose at 1–2 mg/week. Stopping entirely typically leads to substantial regain — SURMOUNT-4 showed about 14% body weight regain over 52 weeks after discontinuation.
Related
Dosing →
Reach your maintenance dose with the standard titration schedule.
Diet & lifestyle →
What to eat to maximize loss and minimize muscle loss.
Microdosing →
For maintenance dosing after reaching goal weight.